摘要
为探讨心钠素在肝硬变腹水中的治疗效应,本工作应用人工合成的人心房肽Ⅲ(human Atriopeptin Ⅲ,hAPⅢ,心钠素)治疗8例肝硬变腹水患者,并进行了利尿、利钠等疗效观察.结果发现:静注200μg hAPⅢ后第1小时尿量和尿钠排泄均较对照显著增加,分别由注射前38.83±5.76 ml/h和2.44±0.55 mmol/h增至74.33±12.89 ml/h和5.12±1.07 mmol/h(P<0.05);且尿量、尿钠排泄增加可持续3～4小时;同时观察的尿钾、尿氯排泄量亦有增加;给药60min后肾素—血管紧张素—醛固酮(RAAS),有一定程度的抑制,但未发现统计学差异;血压、心率和血电解质无明显变化.实验结果表明,应用hAPⅢ治疗肝硬变腹水有明显的利尿、利钠作用,由于其只有轻度排钾、排氯作用,在某些方面.优于排钾利尿剂.
In order to investigate the therapeutic action of atrial natriuretic factor in patients with liver cirrhosis and ascites,synthetic human atriopeptin Ⅱ (hAP Ⅲ )was applied to 8 cases of cirrhosis with ascites. It was found that urine volume and sodium excretion increased significantly from 38. 83 ±5. 76ml/h and 2. 44±0. 55 mmol/h to 74. 33±12. 89 ml/h and 5.12±1. 07 mmol/h(P<0. 05) within 1h after intravenous bolus injection of 200μg of hAP Ⅲ . Furthermore, these action could lasted 3-4 h;Urinary potassium and chloride excretion also increased;Reninangiotensin-aldosterone system was supressed to a certain degree at 60 min post-injection ,but has no statistically significance; Blood pressure,heart rate and serum electrolytes were not disordered. The results showed that hAP Ⅲ has significant diuresis and natriuresis on patients with cirrhosis and ascites,and this has some clinical significance.
出处
《胃肠病学和肝病学杂志》
CAS
1992年第1期47-49,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
心房肽Ⅲ
肝硬变
腹水
atriopeptin Ⅲ atrial natriuretic factor liver cirrhosis ascites diuresis natri-uresis
